Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA

Neuropsychopharmacology

Volumn 35, Issue 7, 2010, Pages 1500-1509

  MacCarrone, Mauro ^a,b   Rossi, Silvia ^b,c   Bari, Monica ^b,d   De Chiara, Valentina ^b,c   Rapino, Cinzia ^a,b   Musella, Alessandra ^b,c   Bernardi, Giorgio ^b,c   Bagni, Claudia ^e,f   Centonze, Diego ^b,c  

^a Dipartimento di Scienze Biomediche Comparate   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Clinica Neurologica   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

2 AG; Anandamide; DHPG; Fragile X; IPSC; Synaptic plasticity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID RECEPTOR; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FRAGILE X MENTAL RETARDATION PROTEIN; LIPOPROTEIN LIPASE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR; RNA; RNA BRAIN CYTOPLASMIC 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; GENE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; SYNAPSE;

ANIMALS; ARACHIDONIC ACIDS; CORPUS STRIATUM; ENDOCANNABINOIDS; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X MENTAL RETARDATION PROTEIN; GENE EXPRESSION REGULATION; GLYCERIDES; INHIBITORY POSTSYNAPTIC POTENTIALS; LIPOPROTEIN LIPASE; MEMBRANE POTENTIALS; METHOXYHYDROXYPHENYLGLYCOL; MICE; MICE, KNOCKOUT; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RECEPTORS, KAINIC ACID; RNA, SMALL CYTOPLASMIC; STATISTICS, NONPARAMETRIC; TETRAHYDROCANNABINOL;

EID: 77952421253     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.19     Document Type: Article

References (41)

1. Bagni C, Greenough WT (2005). From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 6: 376-387.
2. Bassell GJ, Warren ST (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214.
3. Bear MF, Huber KM, Warren ST (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370-377.
4. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A et al (2006). Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761: 205-212.
5. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid knockout in the brain. J Cell Biol 163: 463-468.
6. Bonsi P, Platania P, Martella G, Madeo G, Vita D, Tassone A et al (2008). Distinct roles of group I mGlu receptors in striatal function. Neuropharmacology 55: 392-395.
7. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, De Chiara V et al (2008). Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 63: 963-973.
8. Centonze D, Rossi S, Napoli I, Mercaldo V, Lacoux C, Ferrari F et al (2007a). The brain cytoplasmic RNA BC1 regulates dopamine D2 receptor-mediated transmission in the striatum. J Neurosci 27: 8885-8892.
9. Centonze D, Rossi S, Prosperetti C, Gasperi V, De Chiara V, Bari M et al (2007b). Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons. Mol Cell Neurosci 35: 302-310.
10. Di Marzo V, Maccarrone M (2008). FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 29: 229-233.
11. Ding J, Peterson JD, Surmeier DJ (2008). Corticostriatal and thalamostriatal synapses have distinctive properties. J Neurosci 28: 6483-6492.
12. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
13. Dölen G, Bear MF (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586: 1503-1508.
14. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S et al (2007). Correction of fragile X syndrome in mice. Neuron 56: 955-962.
15. Domenici MR, Potenza RL, Martire A, Coccurello R, Pèzzola A, Reggio R et al (2005). Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinsons disease. J Neurosci Res 80: 646-654.
16. Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T et al (2007). The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34: 343-354.
17. Freund LS, Reiss AL (1991). Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet 38: 542-547.
18. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D (2000). Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol 408: 161-168.
19. Hagerman RJ (2006). Lessons from fragile X regarding neurobiol-ogy, autism, and neurodegeneration. J Dev Behav Pediatr 27: 63-74.
20. Hoover HS, Blankman JL, Niessen S, Cravatt BF (2008). Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett 18: 5838-5841.
21. Huber KM, Gallagher SM, Warren ST, Bear MF (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99: 7746-7750.
22. Huber KM, Kayser MS, Bear MF (2000). Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288: 1254-1257.
23. Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, Khalili K et al (2006). Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res 83: 929-943.
24. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M et al (2005). Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68: 1196-1202.
25. Maccarrone M, De Chiara V, Gasperi V, Viscomi MT, Rossi S, Oddi S et al (2009). Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J Neurochem 109: 371-381.
26. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A et al (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11: 152-159.
27. Menon V, Leroux J, White CD, Reiss AL (2004). Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci USA 101: 3615-3620.
28. Napoli I, Mercaldo V, Pilo Boyl P, Eleuteri B, Zalfa F, De Rubeis S et al (2008). The fragile X mental retardation protein represses activity-dependent translation through CYFIP1, a new 4E-BP'. Cell 134: 1042-1054.
29. Narushima M, Uchigashima M, Fukaya M, Matsui M, Manabe T, Hashimoto K et al (2007). Tonic enhancement of endocannabi-noid-mediated retrograde suppression of inhibition by choliner-gic interneuron activity in the striatum. J Neurosci 27: 496-506.
30. Schuman EM, Dynes JL, Steward O (2006). Synaptic regulation of translation of dendritic mRNAs. J Neurosci 26: 7143-7146.
31. Shin CY, Kundel M, Wells DG (2004). Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation. J Neurosci 24: 9425-9433.
32. Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30: 228-235.
33. Sutton MA, Schuman EM (2006). Dendritic protein synthesis, synaptic plasticity, and memory. Cell 1: 49-58.
34. Wang H, Iacoangeli A, Lin D, Williams K, Denman RB, Hellen CU et al (2005). Dendritic BC1 RNA in translational control mechanisms. J Cell Biol 171: 811-821.
35. Wang H, Iacoangeli A, Popp S, Muslimov IA, Imataka H, Sonenberg N et al (2002). Dendritic BC1 RNA: functional role in regulation of translation initiation. J Neurosci 22: 10232-10241.
36. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K et al (1997). Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci USA 94: 5395-5400.
37. Wilson BM, Cox CL (2007). Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci USA 104: 2454-2459.
38. Zalfa F, Achsel T, Bagni C (2006). mRNPs, polysomes or granules: FMRP in neuronal protein synthesis. Curr Opin Neurobiol 16: 265-269.
39. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S et al (2003). The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112: 317-327.
40. Zhong J, Chuang SC, Bianchi R, Zhao W, Lee H, Fenton AA et al (2009). BC1 regulation of metabotropic glutamate receptor-mediated neuronal excitability. J Neurosci 29: 9977-9986.
41. Zukin R, Richter JD, Bagni C (2009). Signals, synapses, and synthesis: how new proteins control plasticity. Front Neural Circuits 3: 14, doi:10.3389/neuro.04.014.2009.